New stock news | Anchoring Biology submits application to Hong Kong Stock Exchange

According to the disclosure by the Hong Kong Stock Exchange on February 12th, Suzhou Immune Navigation Biology Technology Co., Ltd. (referred to as Immune Navigation) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Huatai International as its exclusive sponsor. The prospectus shows that Immune Navigation is a leader in synthetic biology driven by technological innovation, dedicated to providing green and sustainable, high-efficiency, and cost-competitive bio-based products. The company's products have a leading position in the relevant markets. In terms of active pharmaceutical ingredients and intermediates, according to SCS Consultancy, after achieving large-scale production of fluorobenzenesulfonamide by 2025, based on revenue for the nine months ended September 30, 2025, the company had a market share of 24.5% in the same period, ranking second in the global fluorobenzenesulfonamide industry; based on revenue for the nine months ended September 30, 2025 (including internal and external sales), the company's market share of D-ethyl ester was 44.5%, ranking first in the global D-ethyl ester industry.